Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331630 · ClinicalTrials.gov registry record · Early Phase 1
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT00331630 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT00331630, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage III breast cancer.
Interventions
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-05-04 |
| Est. Completion | 2010-08-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331630
The ClinicalTrials.gov registry entry for NCT00331630 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel albumin-stabilized nanoparticle formulation is the first listed.
NCT00331630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331630 about?
NCT00331630 is a clinical study titled "Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane toge...
What is the current status of trial NCT00331630?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2006-05-04. Estimated completion is 2010-08-05.
What interventions are being tested in trial NCT00331630?
The interventions under investigation include: paclitaxel albumin-stabilized nanoparticle formulation (DRUG), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00331630?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.